- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- Worldwide Increase in Young Colorectal Cancer Patients Linked to “Junk Food”
- Mycoplasma Pneumonia: Another “COVID-19” Outbreak in China?
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- What is the difference between Atorvastatin and Rosuvastatin?
- How long can the patient live after heart stent surgery?
COVID-19: mRNA Vaccine Better Than Recombinant Protein Vaccine
COVID-19: mRNA Vaccine Better Than Recombinant Protein Vaccinem. RNA vaccine vs. recombinant protein vaccine, which is better?
The development of an effective anti-SARS-CoV-2 vaccine is critical to the COVID-19 pandemic. Pfizer and BioNTech jointly announced on the 18th of this month that the final efficacy analysis of the phase three clinical trial showed that more than 43,000 subjects in the phase three clinical trial produced 170 confirmed cases, and there were 162 cases in the placebo group. Only 8 cases were observed in the vaccine-administered group, the vaccine effective rate was 95%, and severe COVID-19 pneumonia can be prevented.
On November 21, mRNA vaccine research and development company Acuitas and Duke University researchers jointly published an article “SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation” on Immunity, comparing the mRNA of the new coronavirus The effect of vaccines and protein vaccines.
The researchers compared the effects of the new coronavirus S protein mRNA vaccine and protein vaccine (M59-like adjuvant) in immunizing mice, and found that the mRNA vaccine has GC response, Tfh activation, neutralizing antibody production, specific memory B cells, and long life. Plasma cells (long-lived plasma cells) are significantly better than protein vaccines.
• The SARS-CoV-2 mRNA vaccine induced an effective germinal center (GC) B cell response
•GC reaction is related to the stable development of neutralizing antibodies
• SARS-CoV-2 mRNA vaccine promotes antigen-specific T follicular helper cells (Tfh)
• The key element of the Tfh cell project is regulated by the SARS-CoV-2 mRNA vaccine
- Single immunization with SARS-CoV-2 mRNA vaccine can produce strong GC B cell response.
- The SARS-CoV-2 mRNA vaccine caused a strong antigen-specific GC B cell response.
- SARS-CoV-2 mRNA vaccination can induce antigen-specific MBC-neutrophil precursors and real MBC.
- Immunization with SARS-CoV-2 mRNA can increase IgG titers and nAbs.
- SARS-CoV-2 mRNA vaccine causes strong differentiation of antigen-specific Tfh cells.
- The SARS-CoV-2 mRNA vaccine drives the high expression of Tfh marker molecules.
- Intensified immunization with SARS-CoV-2 mRNA vaccine can induce stable GCs and nAbs.
The results showed that mRNA vaccines are significantly better than protein vaccines in terms of GC response, Tfh activation, neutralizing antibody production, specific memory B cells, and long-lived plasma cells (LLPC).